Results 131 to 140 of about 101,527 (239)

Fn14 Controls the SIRT2‐Mediated Deacetylation of Slug to Inhibit the Metastasis of Epithelial Ovarian Cancer

open access: yesAdvanced Science, EarlyView.
It is reported that Fn14 inhibited EOC metastasis by regulating Slug‐mediated EMT. Furthermore, Fn14 altered the subcellular localization of SIRT2 by interacting with SIRT2, leading to reduced SIRT2 shuttling into the nucleus and subsequently promoting the acetylated degradation of Slug.
Anyue Wu   +9 more
wiley   +1 more source

Prediction of the potency of mammalian cyclooxygenase inhibitors with ensemble proteochemometric modeling. [PDF]

open access: yesJ Cheminform, 2015
Cortes-Ciriano I   +4 more
europepmc   +1 more source

Potent Cross‐neutralizing Antibodies Reveal Vulnerabilities of Henipavirus Fusion Glycoprotein

open access: yesAdvanced Science, EarlyView.
Hendra and Nipah viruses (HNVs) pose significant threats to global health. This work reports potent cross‐neutralizing antibodies targeting the fusion glycoprotein (F) and reveals shared features of these antibodies and vulnerabilities of F, thereby guiding the rational design of countermeasures against HNVs and similar pathogens.
Yi Ren   +19 more
wiley   +1 more source

Genetic Regulation of Alternative Polyadenylation Provides Novel Insights into Molecular Mechanisms Underlying Non‐small Cell Lung Cancer

open access: yesAdvanced Science, EarlyView.
Compared with the non‐risk G allele of rs9606, the risk T allele of rs9606 decreases the binding affinity of NUDT21 for LYRM4, triggering 3'UTR shortening that stabilizes LYRM4 mRNA and elevates its expression. Increased LYRM4 expression promoted malignant phenotypes of non‐small cell lung cancer (NSCLC) cells through modulating ferroptosis, supporting
Meng Jin   +11 more
wiley   +1 more source

Inhibiting FAT1 Blocks Metabolic Bypass to Enhance Antitumor Efficacy of TCA Cycle Inhibition through Suppressing CPT1A‐Dependent Fatty Acid Oxidation

open access: yesAdvanced Science, EarlyView.
This study demonstrates that mutant FAT1 promotes ASCL2‐driven, CPT1A‐dependent fatty acid oxidation, leading to resistance to CPI‐613‐mediated TCA cycle inhibition in head and neck cancer. In vivo gene depletion of mutant FAT1 with LNP‐sgFAT1 suppresses tumor growth and restores CPI‐613 sensitivity, revealing a targetable metabolic bypass with ...
Fanghui Chen   +11 more
wiley   +1 more source

Fragment Autoantigens Stimulated T‐Cell‐Immunotherapy (FAST) as a Fast Autologous Cancer Vaccine

open access: yesAdvanced Science, EarlyView.
A personalized whole tumor cell vaccine (FAST) is developed to address immunosuppressive tumor microenvironments and genomic instability‐driven heterogeneity. Irradiation and cryoablation‐treated tumor cells generate fragmented antigens (FAs) that activate broad‐spectrum antigen presentation via upregulated immunogenic cell death, MHC‐I, and damage ...
Yuan Li   +14 more
wiley   +1 more source

C1q+ Macrophage–Tumor Cell Interaction Promoted Tumorigenesis via GPR17/PI3K/AKT Pathway Induced DNA Hypermethylation in Nasopharyngeal Carcinoma

open access: yesAdvanced Science, EarlyView.
In the TME of NPC, C1q secreted by C1q+ TAMs interacted with GPR17 to activate PI3K/AKT signaling through strengthening GPR17 coupling PI3K and increasing calcium levels in tumor cells. The activated PI3K/AKT signaling further induces DNA hypermethylation to promote the malignancy and stemness of tumor cells.
Yunzhi Liu   +11 more
wiley   +1 more source

Targeted Penetrating Motif Engineering of BH3 Mimetic: Harnessing Non‐Canonical Amino Acids for Coinhibition of MCL‐1 and BCL‐xL in Acute Myeloid Leukemia

open access: yesAdvanced Science, EarlyView.
A structure‐guided peptide derived from a non‐canonical amino acid library simultaneously targets MCL‐1 and BCL‐xL to overcome apoptotic resistance in acute myeloid leukemia. Fused with a CXCR4‐binding motif, the engineered peptide exhibits selective intracellular delivery and potent in vivo efficacy, offering a promising therapeutic strategy against ...
Zhe Wang   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy